Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14646187 | 0.84 | KDM4E (0.71) | KDM4EHSD17B10APEX1PTGDR2ALDH1A1 | |
| SCHEMBL15643888 | 0.82 | HSD17B10 (1.00) | KDM4EHSD17B10APEX1PTGDR2ALDH1A1 | |
| SCHEMBL14646191 | 0.82 | HSD17B10 (0.94) | KDM4EHSD17B10APEX1PTGDR2ALDH1A1 | |
| SCHEMBL3587930 | 0.77 | KDM4E (0.69) | KDM4EHSD17B10APEX1PTGDR2ALDH1A1 | |
| SCHEMBL4292873 | 0.74 | KDM4E (0.65) | KDM4EHSD17B10APEX1PTGDR2ALDH1A1 | |
| SCHEMBL4288066 | 0.74 | KDM4E (0.65) | KDM4EHSD17B10APEX1PTGDR2ALDH1A1 | |
| SCHEMBL11145191 | 0.74 | KDM4E (0.65) | KDM4EHSD17B10APEX1PTGDR2ALDH1A1 | |
| SCHEMBL27799061 | 0.74 | KDM4E (0.72) | KDM4EHSD17B10APEX1ALDH1A1MEN1 | |
| SCHEMBL10611483 | 0.73 | KDM4E (0.63) | KDM4EHSD17B10APEX1PTGDR2ALDH1A1 | |
| SCHEMBL28141462 | 0.73 | KDM4E (0.75) | KDM4EHSD17B10PTGDR2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359311-B2 | Substituted aromatic oligomers | NEUROSCIOS GMBH (AT) | 2016-06-07 | — | — | US | disclosed |
| US-9359311-B2 | Substituted aromatic oligomers | NEUROSCIOS GMBH (AT) | 2016-06-07 | — | — | US | disclosed |
| US-20140135322-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BIOCHROMIX PHARMA AB | 2014-05-15 | — | — | US | disclosed |
| US-20140135322-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BIOCHROMIX PHARMA AB | 2014-05-15 | — | — | US | disclosed |
| WO-2013036196-A1 | NOVEL THIOPHENE COMPOUNDS AND METHOD FOR IN VIVO IMAGING | BIOCHROMIX AB (SE) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013009259-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BIOCHROMIX PHARMA AB (SE) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135322-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | PRNP, TBCA, HSPA5 | KDM4E 4549/4885HSD17B10 1758/4885APEX1 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.